AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30883904 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 341
Study 27564775 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (2 mg per day, 15 days, three courses in total)
Number of subjects: 96
Study 27564775 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular therapy with thymopentin
Number of subjects: 96
Study 27564775 — intervention group
Group type: COMPARATOR
Intervention: Regular therapy (control group)
Number of subjects: 96
Study 25260193 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclaimer on airbrushed thin ideal images
Number of subjects: 48
Study 25260193 — intervention group
Group type: COMPARATOR
Intervention: Neutral sentence
Number of subjects: 48
Study 25260193 — intervention group
Group type: COMPARATOR
Intervention: No text
Number of subjects: 48
Study 23030241 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 1.2% ATV
Number of subjects: 60
Study 23030241 — intervention group
Group type: COMPARATOR
Intervention: SRP plus placebo gel
Number of subjects: 60
Study 21723205 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-temporal atrophy (MTA)
Number of subjects: 1349
Study 21723205 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter hyperintensities (WMH)
Number of subjects: 1349
Study 21723205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral atrophy (CA)
Number of subjects: 1349
Study 21723205 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI infarcts
Number of subjects: 1349
Study 21723205 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA and WMH
Number of subjects: 1349
Study 21723205 — intervention group
Group type: EXPERIMENTAL
Intervention: WMH
Number of subjects: 1349
Study 19893824 — intervention group
Group type: EXPERIMENTAL
Intervention: Written invitation to attend a case finding appointment with the practice nurse, including spirometry
Number of subjects: 400
Study 19893824 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 400
Study 16501408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses (daily wear)
Number of subjects: 45
Study 16501408 — intervention group
Group type: EXPERIMENTAL
Intervention: Balafilcon A lenses (daily wear)
Number of subjects: 45
Study 16501408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses (continuous wear)
Number of subjects: 45
Study 16501408 — intervention group
Group type: EXPERIMENTAL
Intervention: Balafilcon A lenses (continuous wear)
Number of subjects: 45
Study 16501408 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-contact lens wearers)
Number of subjects: 45
Study 15142868 — intervention group
Group type: EXPERIMENTAL
Intervention: Stringent environmental control (active)
Number of subjects: 251
Study 15142868 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 251
Study 11712772 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based technology for clinical trial management
Number of subjects: 0
Study 11712772 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based software for site training, study documentation, subject recruitment, randomization, medication dispensing, and management procedures
Number of subjects: 0
Study 9520963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up protocol (multiple attempts via mail and telephone)
Number of subjects: 1453
Study 9520963 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic vouchers to offset out-of-pocket expenses
Number of subjects: 1453
Study 9520963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up plus voucher condition
Number of subjects: 1453
Study 9520963 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 1453
Study 7999596 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate treatment
Number of subjects: 26
Study 7999596 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 26
Study 7999596 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 26
Study 2626514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine (mixed D1/D2 dopamine antagonist)
Number of subjects: 15
Study 2626514 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 776193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.3 mg/kg i.v. with food intake at 3 hours post-injection
Number of subjects: 13
Study 776193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.3 mg/kg i.v. with food intake at 7 hours post-injection
Number of subjects: 13
Study 776193 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcoal ingestion in six subjects
Number of subjects: 13
Study 776193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg/kg i.v. with rapid injection
Number of subjects: 13
Study 6785095 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 40 microgram/kg via 30 min i.v. infusion
Number of subjects: 18
Study 29732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling efforts
Number of subjects: 30
Study 29732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based interventions
Number of subjects: 30
Study 30153839 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions including economic support to families, payment of school fees, pocket money for girls, youth club and community meetings on reproductive health.
Number of subjects: 0
Study 30153839 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of adolescent sexual reproductive health and rights (SRHR) interventions into community health systems.
Number of subjects: 0
Study 26974423 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST treatment (20 mL/kg of crystalloid over 10 min)
Number of subjects: 9
Study 26974423 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOW treatment (20 mL/kg of crystalloid over 30 min)
Number of subjects: 9
Study 26974423 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST treatment
Number of subjects: 9
Study 26974423 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOW treatment
Number of subjects: 9
Study 26974423 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FAST and SLOW treatments
Number of subjects: 9
Study 25363189 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B1 (100 mg/day)
Number of subjects: 240
Study 25363189 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (500 mg/day)
Number of subjects: 240
Study 25363189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Vitamin B1 and Fish oil
Number of subjects: 240
Study 25363189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 22267420 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg daily before bedtime for 30 days
Number of subjects: 60
Study 22267420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19895779 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 1452
Study 17490746 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial medical therapy
Number of subjects: 607
Study 17490746 — intervention group
Group type: COMPARATOR
Intervention: Initial trabeculectomy
Number of subjects: 607
Study 15235913 — intervention group
Group type: EXPERIMENTAL
Intervention: Practiced with one hand
Number of subjects: 0
Study 15235913 — intervention group
Group type: EXPERIMENTAL
Intervention: Practiced with two hands
Number of subjects: 0
Study 12399283 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT group (37% MCT, 63% LCT)
Number of subjects: 0
Study 12399283 — intervention group
Group type: COMPARATOR
Intervention: LCT group (100% LCT)
Number of subjects: 0
Study 10453964 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg abacavir hemisulfate tablet (oral)
Number of subjects: 24
Study 10453964 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg abacavir hemisulfate tablet with food
Number of subjects: 24
Study 10453964 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir (various formulations)
Number of subjects: 24
Study 7840258 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary pressure measurement in women
Number of subjects: 74
Study 7840258 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary pressure measurement in men
Number of subjects: 74
Study 7840258 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary pulse pressure amplitude related to skin temperature in women
Number of subjects: 74
Study 7840258 — intervention group
Group type: EXPERIMENTAL
Intervention: Time taken for systolic pressure rise to reach capillary in women
Number of subjects: 74
Study 7840258 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency waves in pressure waveform related to age
Number of subjects: 74
Study 2195528 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (50 ng kg‐1 min‐1)
Number of subjects: 16
Study 2195528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Normal saline)
Number of subjects: 16
Study 721343 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone patients
Number of subjects: 0
Study 721343 — intervention group
Group type: COMPARATOR
Intervention: Nonaddict control group
Number of subjects: 0
Study 31789786 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced lay observers
Number of subjects: 205
Study 31789786 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional graders from DIRC
Number of subjects: 205
Study 31789786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculoplastic experts
Number of subjects: 205
Study 31789786 — intervention group
Group type: COMPARATOR
Intervention: Lay observers
Number of subjects: 205
Study 31789786 — intervention group
Group type: COMPARATOR
Intervention: DIRC graders
Number of subjects: 205
Study 31190735 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab (fully human monoclonal antibody targeting IFNAR1)
Number of subjects: 0
Study 31190735 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 0
Study 31190735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27834474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 18
Study 25483366 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol (140 μg weekly)
Number of subjects: 57
Study 25483366 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol (140 μg weekly)
Number of subjects: 57
Study 21932396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 257
Study 21932396 — intervention group
Group type: COMPARATOR
Intervention: Control group (half-day psycho-educational seminar)
Number of subjects: 257
Study 21831348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice with 5000ppm fluoride
Number of subjects: 16
Study 21831348 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice with 1450ppm fluoride
Number of subjects: 16
Study 19771283 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC isotonic exercise
Number of subjects: 24
Study 19771283 — intervention group
Group type: COMPARATOR
Intervention: CON-ECC isokinetic exercise
Number of subjects: 24
Study 19771283 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 17893310 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 4573
Study 17893310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4573
Study 15564936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-pancuronium
Number of subjects: 30
Study 15564936 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-midazolam-pancuronium
Number of subjects: 30
Study 11726266 — intervention group
Group type: EXPERIMENTAL
Intervention: Overhydrated (OH)
Number of subjects: 11
Study 11726266 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated (EUH)
Number of subjects: 11
Study 9409369 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported dependency assessment
Number of subjects: 0
Study 8287583 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b (IFN) therapy for 24 weeks
Number of subjects: 68
Study 8287583 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 68
Study 3566601 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% pilocarpine nitrate
Number of subjects: 23
Study 3566601 — intervention group
Group type: COMPARATOR
Intervention: Control eye (no treatment)
Number of subjects: 23
Study 31062999 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Wingate All‐Out Performance Test (WG)
Number of subjects: 32
Study 31062999 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 32
Study 28141897 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) with low-dose tacrolimus (LTac) and prednisone
Number of subjects: 309
Study 25721183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SRT, n = 133)
Number of subjects: 488
Study 25721183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT, n = 139)
Number of subjects: 488
Study 25721183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both (COMB, n = 140)
Number of subjects: 488
Study 25721183 — intervention group
Group type: COMPARATOR
Intervention: Pill Placebo (PBO, n = 76)
Number of subjects: 488
Study 25721183 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 488
Study 23937345 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) augmentation of cognitive behavioral therapy (CBT)
Number of subjects: 169
Study 23937345 — intervention group
Group type: COMPARATOR
Intervention: Placebo augmentation of cognitive behavioral therapy (CBT)
Number of subjects: 169
Study 23937345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 169
Study 21521468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (NM) 0.02 mg/kg
Number of subjects: 62
Study 21521468 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 62
Study 18046527 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2022
Study 18046527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2022
Study 16925689 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerant patients (n = 29)
Number of subjects: 29
Study 16925689 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically reactive non-IgE-mediated CMA patients (n = 10)
Number of subjects: 29
Study 16925689 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE-mediated CMA patients (n = 19)
Number of subjects: 29
Study 14536040 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype Mk IV implant (test)
Number of subjects: 44
Study 14536040 — intervention group
Group type: COMPARATOR
Intervention: Brånemark implant (control)
Number of subjects: 44
Study 14536040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and control implants
Number of subjects: 44
Study 14536040 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implants
Number of subjects: 44
Study 14536040 — intervention group
Group type: COMPARATOR
Intervention: Control implants
Number of subjects: 44
Study 10936478 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation thrombolytic agents (monteplase, tenecteplase, reteplase, lanoteplase, pamiteplase, staphylokinase)
Number of subjects: 0
Study 10936478 — intervention group
Group type: COMPARATOR
Intervention: Second-generation agent (alteplase)
Number of subjects: 0
Study 10936478 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation thrombolytic agents
Number of subjects: 0
Study 8656336 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures (locus-of-control scale)
Number of subjects: 480
Study 8656336 — intervention group
Group type: EXPERIMENTAL
Intervention: Content engagement process (Study 2)
Number of subjects: 480
Study 1727274 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging at 0.5 T
Number of subjects: 11
Study 1727274 — intervention group
Group type: COMPARATOR
Intervention: CT imaging
Number of subjects: 11
Study 1727274 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 11
Study 1727274 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging compared to CT
Number of subjects: 11
Study 1727274 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging compared to chest radiography
Number of subjects: 11
Study 1727274 — intervention group
Group type: EXPERIMENTAL
Intervention: Short inversion time inversion-recovery sequences
Number of subjects: 11
Study 6837243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg body weight
Number of subjects: 19
Study 6837243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 19
Study 31652166 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/d of brexpiprazole
Number of subjects: 1094
Study 31652166 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/d of brexpiprazole
Number of subjects: 1094
Study 31652166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1094
Study 30014662 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus rehabilitation training plus acupuncture (observation 2 group)
Number of subjects: 78
Study 30014662 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus rehabilitation training (observation 1 group)
Number of subjects: 78
Study 30014662 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (control group)
Number of subjects: 78
Study 25689448 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1,600 mg
Number of subjects: 193
Study 25689448 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1,200 mg
Number of subjects: 193
Study 25689448 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 193
Study 23637031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ansell Perry Orthopaedic (thickest glove)
Number of subjects: 42
Study 23637031 — intervention group
Group type: COMPARATOR
Intervention: Non-sterile glove
Number of subjects: 42
Study 23637031 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex-free, powder-free (Cardinal Esteem)
Number of subjects: 42
Study 23637031 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex powder-free (Mölnlycke-Biogel)
Number of subjects: 42
Study 23637031 — intervention group
Group type: EXPERIMENTAL
Intervention: All glove types
Number of subjects: 42
Study 22029225 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole formulation 1
Number of subjects: 20
Study 22029225 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole formulation 2
Number of subjects: 20
Study 18801669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of autogenous bone and BioOss
Number of subjects: 0
Study 18801669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of BioOss and Orthoblast II
Number of subjects: 0
Study 18801669 — intervention group
Group type: EXPERIMENTAL
Intervention: BioOss only
Number of subjects: 0
Study 18801669 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic bone, Osteon only
Number of subjects: 0
Study 18801669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of allogeneic and xenogeneic bone
Number of subjects: 0
Study 17076453 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 11
Study 17076453 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon (10 mg)
Number of subjects: 11
Study 17076453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15648985 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 25 mg
Number of subjects: 120
Study 15648985 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 15 mg
Number of subjects: 120
Study 15648985 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 120
Study 11329407 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day of sustained‐release bupropion
Number of subjects: 30
Study 11329407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8301105 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (less than 50 mmol/day)
Number of subjects: 187
Study 8301105 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-salt diet (not specified)
Number of subjects: 187
Study 8301105 — intervention group
Group type: COMPARATOR
Intervention: High-salt diet (greater than 200 mmol/day)
Number of subjects: 187
Study 8301105 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt loading (prospective study)
Number of subjects: 187
Study 8301105 — intervention group
Group type: COMPARATOR
Intervention: Salt sensitivity
Number of subjects: 187
Study 3307309 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin at 40 IU/ml (U40)
Number of subjects: 46
Study 3307309 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin at 100 IU/ml (U100)
Number of subjects: 46
Study 29461856 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally assisted collaborative telecare (CACT)
Number of subjects: 666
Study 29461856 — intervention group
Group type: COMPARATOR
Intervention: Optimized usual care (OUC)
Number of subjects: 666
Study 27054798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy with native tissue vault suspension
Number of subjects: 180
Study 27054798 — intervention group
Group type: COMPARATOR
Intervention: Mesh hysteropexy suspension
Number of subjects: 180
Study 27054798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 180
Study 26271057 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of 6 risk factors (no smoking, non-HDL cholesterol <130 mg/dl, triglycerides <150 mg/dl, blood pressure systolic <130 mm Hg; diastolic <80 mm Hg, glycosylated hemoglobin <7%)
Number of subjects: 2265
Study 26271057 — intervention group
Group type: COMPARATOR
Intervention: Control of 0 to 2 risk factors during follow-up
Number of subjects: 2265
Study 26271057 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of 6 risk factors during follow-up
Number of subjects: 2265
Study 23675549 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministered treatment (ivermectin/albendazole/azithromycin)
Number of subjects: 3011